news
Protein identified as potential target for leishmaniasis vaccines
New research has demonstrated in mouse models that the SHP-1 protein limits the capacity of dendritic cells, making it a target for a leishmaniasis vaccine.
List view / Grid view
Leishmaniasis
news
Using CRISPR to develop a cutaneous leishmaniasis vaccine
Researchers used CRISPR gene-editing to develop a vaccine able to protect against the spread of the Leishmania major parasite which causes cutaneous leishmaniasis.
article
Flow cytometry in neglected tropical diseases – a focus on leishmaniasis
The World Health Organization (WHO) identifies leishmaniasis as a neglected tropical disease for which new treatments are vitally needed. Leishmaniasis primarily affects people in South America, East Africa and Asia, especially those weakened by malnutrition and poverty. To help those with this disfiguring and potentially life-threatening parasitic disease, the European…
article
Hit-to-lead in neglected diseases – it’s a numbers game
The hit-to-lead journey can be a long endeavour, with many failures along the way. Nikki Withers spoke with DNDi ’s Discovery Director Dr Charles Mowbray to hear how the organisation is working to identify new leads with activity in animal models of neglected tropical diseases and the potential for further…
article
The challenges of hit-to-lead in drug discovery
A study that identified 12 novel compounds that may prove valuable against new drug targets for leishmaniasis and Chagas disease was not without complication. Here, we discuss the findings but also the challenges the researchers reported in their hit-to-lead study.
news
Study identifies virulence factors of Leishmania
Researchers have discovered the mechanism behind the spread of Leishmania, indicating a potential drug target.
news
KSRP discovery gives a potential therapeutic target to combat trypanosomes
Researchers have discovered a new potential therapeutic target – located in the ribosome – to combat trypanosomes parasites...
news
Potential targets for treatment of leishmaniasis identified
Brazilian scientists show that parasite's penetration of host cells increases expression of certain microRNAs capable of inhibiting the action of the immune system...
news
Optibrium, Imperial College and DNDi to collaborate on drug development
The collaboration will provide MSc students with industry-relevant learning tools and pharma with a new pipeline of candidate compounds.
news
Daiichi Sankyo to collaborate on drugs for neglected tropical diseases
Daiichi Sankyo has entered into a new joint research agreement with the Drugs for Neglected Diseases initiative (DNDi) with regard to a new research program, the Hit-to-Lead Project, with the aim of developing drug treatments for two neglected tropical diseases, leishmaniasis and Chagas disease.
news
Killing three deadly diseases with one compound
9 August 2016 | By Niamh Louise Marriott, Digital Content Producer
Three diseases; Chagas disease, leishmaniasis and sleeping sickness, all caused by parasites called ‘kinetoplastids, all sharing similar biology and genetics, leading scientists to investigate the possibility of a single chemical to destroy all three...
news
TB drug could also target visceral leishmaniasis
24 May 2016 | By Victoria White, Digital Content Producer
Delamanid could also be a powerful tool to combat visceral leishmaniasis researchers at the University of Dundee have found...
